Avantor (NYSE:AVTR) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen lowered shares of Avantor (NYSE:AVTR – Free Report) from a buy rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Other research analysts have also issued research reports about the stock. Evercore set a $10.50 target price on shares of Avantor in a research note on Monday, July 6th. Sanford C. Bernstein began coverage on shares of Avantor in a research note on Friday, June 26th. They set a “market perform” rating and a $10.50 price target for the company. Morgan Stanley increased their price objective on shares of Avantor from $10.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Wells Fargo & Company raised their price objective on shares of Avantor from $14.00 to $16.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Finally, Jefferies Financial Group raised shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 target price for the company in a report on Wednesday, July 29th. Two research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $12.47.

Check Out Our Latest Stock Report on AVTR

Avantor Stock Performance

Shares of Avantor stock opened at $15.35 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.78 and a quick ratio of 1.18. The firm has a 50 day simple moving average of $14.44 and a 200 day simple moving average of $10.84. Avantor has a fifty-two week low of $7.26 and a fifty-two week high of $16.05. The firm has a market cap of $10.38 billion, a P/E ratio of -18.27, a P/E/G ratio of 11.58 and a beta of 0.94.

Avantor (NYSE:AVTR – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.02. The business had revenue of $1.69 billion for the quarter, compared to analysts’ expectations of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter last year, the business earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Sell-side analysts predict that Avantor will post 0.81 earnings per share for the current fiscal year.

Institutional Trading of Avantor

A number of hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Avantor during the second quarter valued at approximately $695,784,000. Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in Avantor in the second quarter worth $195,386,000. Clarkston Capital Partners LLC raised its holdings in Avantor by 0.6% in the fourth quarter. Clarkston Capital Partners LLC now owns 15,105,065 shares of the company’s stock worth $173,104,000 after purchasing an additional 84,740 shares during the period. Engine Capital Management LP boosted its position in shares of Avantor by 65.8% during the first quarter. Engine Capital Management LP now owns 19,780,830 shares of the company’s stock worth $155,082,000 after purchasing an additional 7,853,018 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Avantor by 15.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 16,894,649 shares of the company’s stock valued at $132,443,000 after buying an additional 2,288,053 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Avantor

(Get Free Report)

Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.

Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.

See Also

Analyst Recommendations for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.